Current and emerging biomarkers for ulcerative colitis

References

• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–2778.
   PubMed Web of Science ®Google Scholar
• Agrawal M, Christensen HS, Bøgsted M, et al. The rising burden of inflammatory bowel disease in Denmark over two decades: a nationwide cohort study. Gastroenterology. 2022;163(6):1547–1554.e5.
   PubMed Web of Science ®Google Scholar
• Alatab S, Sepanlou SG, Ikuta K, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17–30.
   PubMed Web of Science ®Google Scholar
• Graham DB, Xavier RJ. Pathway paradigms revealed from the genetics of inflammatory bowel disease. Nature. 2020;578(7796):527–539. doi: 10.1038/s41586-020-2025-2
   PubMed Web of Science ®Google Scholar
• Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–s106.
   PubMed Web of Science ®Google Scholar
• Zilbauer M, Heuschkel R. Disease prognostic biomarkers in inflammatory bowel diseases—A reality check. J Crohns Colitis. 2022;16(1):162–165. doi: 10.1093/ecco-jcc/jjab118
   PubMed Web of Science ®Google Scholar
• Honig G, Heller C, Hurtado-Lorenzo A. Defining the path forward for biomarkers to address unmet needs in inflammatory bowel diseases. Inflamm Bowel Dis. 2020;26(10):1451–1462. doi: 10.1093/ibd/izaa210
   PubMed Web of Science ®Google Scholar
• Honig G. Towards a common validated methodology for histologic measurement of mucosal healing in ulcerative colitis: introducing a new project of the biomarkers consortium of the foundation for the nih. Gastroenterology. 2022;162(3):S35. doi: 10.1053/j.gastro.2021.12.071
   Web of Science ®Google Scholar
• Ma C, Hanzel J, Panaccione R, et al. CORE-IBD: a multidisciplinary international consensus initiative to develop a core outcome set for randomized controlled trials in inflammatory bowel disease. Gastroenterology. 2022;163(4):950–964.
   PubMed Web of Science ®Google Scholar
• Plevris N, Lees CW. Disease monitoring in inflammatory bowel disease: evolving principles and possibilities. Gastroenterology. 2022;162(5):1456–1475.e1. doi: 10.1053/j.gastro.2022.01.024
   PubMed Web of Science ®Google Scholar
• Jukic A, Bakiri L, Wagner EF, et al. Calprotectin: from biomarker to biological function. Gut. 2021;70(10):1978–1988.
   PubMed Web of Science ®Google Scholar
• Udegbune M, Sharrod–Cole H, Townsend S, et al. Diagnostic performance of serum calprotectin in discriminating active from inactive ulcerative colitis in an outpatient setting. Ann Clin Biochem. 2022;59(6):404–409.
   PubMed Web of Science ®Google Scholar
• Shimizu H, Ebana R, Kudo T, et al. Both fecal calprotectin and fecal immunochemical tests are useful in children with inflammatory bowel disease. J Gastroenterol. 2022;57(5):344–356.
   PubMed Web of Science ®Google Scholar
• Kim ES, Lee HS, Kim SK, et al. Fecal calprotectin is more accurate than fecal immunochemical test for predicting mucosal healing in quiescent ulcerative colitis: a prospective multicenter study. Scand J Gastroenterol. 2020;55(2):163–168.
   PubMed Web of Science ®Google Scholar
• Kawashima K, Oshima N, Kishimoto K, et al. Low fecal calprotectin predicts histological healing in patients with ulcerative colitis with endoscopic remission and leads to prolonged clinical remission. Inflamm Bowel Dis. 2023;29(3):359–366.
   PubMed Web of Science ®Google Scholar
• Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care—an evidence-based Guideline from European Crohn’s and colitis organization and European Society of paediatric Gastroenterology, hepatology and nutrition. J Pediatr Gastroenterol Nutr. 2018;67(2):257–291.
   PubMed Web of Science ®Google Scholar
• Guardiola J, Lobatón T, Cerrillo E, et al. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la utilidad de la determinación de calprotectina fecal en la enfermedad inflamatoria intestinal. Gastroenterol Hepatol. 2018;41(8):514–529.
   PubMedGoogle Scholar
• Koninckx CR, Donat E, Benninga MA, et al. The use of fecal calprotectin testing in paediatric disorders: a position paper of the European Society for paediatric Gastroenterology and nutrition gastroenterology committee. J Pediatr Gastroenterol Nutr. 2021;72(4):617–640.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Feagan BG, Sands BE, et al. Prognostic value of fecal calprotectin to inform treat-to-target monitoring in ulcerative colitis. Clin Gastroenterol Hepatol. 2023;21(2):456–466.e7.
   PubMed Web of Science ®Google Scholar
• Kamat N, Vuyyuru SK, Kedia S, et al. Correlation of fecal calprotectin and patient-reported outcome measures in patients with ulcerative colitis. Intest Res. 2022;20(2):269–273.
   PubMed Web of Science ®Google Scholar
• Sakuraba A, Nemoto N, Hibi N, et al. Extent of disease affects the usefulness of fecal biomarkers in ulcerative colitis. BMC Gastroenterol. 2021;21(1):197.
   PubMed Web of Science ®Google Scholar
• Pavlidis P, Joshi D, Sherif YE, et al. Faecal calprotectin is a surrogate marker of biliary inflammation in primary sclerosing cholangitis associated inflammatory bowel disease. Frontline Gastroenterol. 2022;13(6):497–502.
   PubMed Web of Science ®Google Scholar
• Kalla R, Boyapati R, Vatn S, et al. Patients’ perceptions of faecal calprotectin testing in inflammatory bowel disease: results from a prospective multicentre patient-based survey. Scand J Gastroenterol. 2018;53(12):1437–1442.
   PubMed Web of Science ®Google Scholar
• Maréchal C, Aimone-Gastin I, Baumann C, et al. Compliance with the faecal calprotectin test in patients with inflammatory bowel disease. United Eur Gastroenterol J. 2017;5(5):702–707.
   PubMed Web of Science ®Google Scholar
• Lasson A, Stotzer P-O, Öhman L, et al. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2015;9:26–32. doi: 10.1016/j.crohns.2014.06.002
   PubMed Web of Science ®Google Scholar
• Kalla R, Kennedy NA, Ventham NT, et al. Serum Calprotectin: a Novel diagnostic and prognostic marker in inflammatory bowel diseases. Am J Gastroenterol. 2016;111(12):1796–1805.
   PubMed Web of Science ®Google Scholar
• Malham M, Carlsen K, Riis L, et al. Plasma calprotectin is superior to serum calprotectin as a biomarker of intestinal inflammation in ulcerative colitis. Scand J Gastroenterol. 2019;54(10):1214–1219.
   PubMed Web of Science ®Google Scholar
• Kessel C, Lavric M, Weinhage T, et al. Serum biomarkers confirming stable remission in inflammatory bowel disease. Sci Rep. 2021;11(1):6690.
   PubMed Web of Science ®Google Scholar
• Mortensen JH, Sinkeviciute D, Manon-Jensen T, et al. A specific calprotectin neo-epitope [CPa9-HNE] in serum from inflammatory bowel disease patients is associated with neutrophil activity and endoscopic severity. J Crohns Colitis. 2022;16(9):1447–1460. doi: 10.1093/ecco-jcc/jjac047
   PubMed Web of Science ®Google Scholar
• Alexdottir MS, Bourgonje AR, Karsdal MA, et al. Serological biomarkers of extracellular matrix turnover and neutrophil activity are associated with long-term use of vedolizumab in patients with Crohn’s disease. Int J Mol Sci. 2022;23(15):8137.
   PubMed Web of Science ®Google Scholar
• Iwańczak B, Ruczka M, Matusiewicz M, et al. Correlation between biomarkers (calprotectin, seromucoid, metalloproteinase-3 and CRP) and clinical and endoscopic activity of ulcerative colitis in children. Adv Med Sci. 2020;65(2):259–264.
   PubMed Web of Science ®Google Scholar
• Yoon JY, Park SJ, Hong SP, et al. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. Dig Dis Sci. 2014;59(4):829–837.
   PubMed Web of Science ®Google Scholar
• Karoui S, Laz S, Serghini M, et al. Correlation of C-reactive protein with clinical and endoscopic activity in patients with ulcerative colitis. Dig Dis Sci. 2011;56(6):1801–1805.
   PubMed Web of Science ®Google Scholar
• Ishida N, Higuchi T, Miyazu T, et al. C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis. Sci Rep. 2021;11(1):12431.
   PubMed Web of Science ®Google Scholar
• Voiosu T, Benguş A, Bălănescu P, et al. Rapid fecal calprotectin Testing predicts mucosal healing better than C-reactive protein and serum tumor necrosis factor α in patients with ulcerative colitis. Romanian J Intern Med Rev Roum Med Interne. 2015;53(3):253–260.
   PubMedGoogle Scholar
• Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19(2):332–341.
   PubMed Web of Science ®Google Scholar
• Deva Rajoo G, Tan L, Lopez A, et al. Early response to corticosteroid and baseline C-Reactive protein predicts outcomes in children with moderate to severe ulcerative colitis. Dig Dis Sci. 2019;64(7):1929–1937.
   PubMed Web of Science ®Google Scholar
• Con D, Andrew B, Nicolaides S, et al. Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy. Intest Res. 2022;20(1):101–113.
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Magro F, Steinwurz F, et al. Association of C-reactive protein and partial Mayo score with response to tofacitinib induction therapy: results from the ulcerative colitis clinical program. Inflamm Bowel Dis. 2022;29(1):51–61.
   Web of Science ®Google Scholar
• Croft A, Lord A, Radford-Smith G. Markers of systemic inflammation in acute attacks of ulcerative colitis: what level of C-reactive protein constitutes severe colitis? J Crohns Colitis. 2022;16(7):1089–1096. doi: 10.1093/ecco-jcc/jjac014
   PubMed Web of Science ®Google Scholar
• Bakkaloglu OK, Eskazan T, Celik S, et al. Can we predict mucosal remission in ulcerative colitis more precisely with a redefined cutoff level of C-reactive protein? Colorectal Dis Off J Assoc Coloproctology G B Irel. 2022;24(1):77–84.
   PubMed Web of Science ®Google Scholar
• Imakiire S, Takedatsu H, Mitsuyama K, et al. Role of serum proteinase 3 antineutrophil cytoplasmic antibodies in the diagnosis, evaluation of disease severity, and clinical course of ulcerative colitis. Gut Liver. 2022;16(1):92–100.
   PubMed Web of Science ®Google Scholar
• Horn MP, Peter AM, Righini Grunder F, et al. PR3-ANCA and panel diagnostics in pediatric inflammatory bowel disease to distinguish ulcerative colitis from Crohn’s disease. PLoS One. 2018;13:e0208974. doi: 10.1371/journal.pone.0208974
   PubMed Web of Science ®Google Scholar
• Xu Y, Xu F, Li W, et al. The diagnostic role and clinical association of serum proteinase 3 anti-neutrophil cytoplasmic antibodies in Chinese patients with inflammatory bowel disease. Scand J Gastroenterol. 2020;55(7):806–813.
   PubMed Web of Science ®Google Scholar
• Lee W-I, Subramaniam K, Hawkins CA, et al. The significance of ANCA positivity in patients with inflammatory bowel disease. Pathology. 2019;51(6):634–639.
   PubMed Web of Science ®Google Scholar
• Laass MW, Ziesmann J, de Laffolie J, et al. Anti-proteinase 3 antibodies as a biomarker for ulcerative colitis and primary sclerosing cholangitis in children. J Pediatr Gastroenterol Nutr. 2022;74(4):463–470.
   PubMed Web of Science ®Google Scholar
• Rydell N, Ekoff H, Hellström PM, et al. Measurement of serum IgG anti-integrin αvβ6 autoantibodies is a promising tool in the diagnosis of ulcerative colitis. J Clin Med. 2022;11(7):1881.
   PubMed Web of Science ®Google Scholar
• Kuwada T, Shiokawa M, Kodama Y, et al. Identification of an anti–integrin αvβ6 autoantibody in patients with ulcerative colitis. Gastroenterology. 2021;160(7):2383–2394.e21.
   PubMed Web of Science ®Google Scholar
• Livanos AE, Dunn A, Fischer J, et al. Anti-Integrin αvβ6 Autoantibodies Are a Novel Biomarker That Antedate Ulcerative Colitis. Gastroenterology. 2023;164(4):619–629. doi: 10.1053/j.gastro.2022.12.042
   PubMed Web of Science ®Google Scholar
• Swaminathan A, Borichevsky GM, Edwards TS, et al. Faecal myeloperoxidase as a biomarker of endoscopic activity in inflammatory bowel disease. J Crohns Colitis. 2022;16(12):1862–1873.
   PubMed Web of Science ®Google Scholar
• Czub E, Nowak JK, Szaflarska-Poplawska A, et al. Comparison of fecal pyruvate kinase isoform M2 and calprotectin in assessment of pediatric inflammatory bowel disease severity and activity. Acta Biochim Pol. 2014;61(1):99–102.
   PubMed Web of Science ®Google Scholar
• Amcoff K, Cao Y, Zhulina Y, et al. Prognostic significance of faecal eosinophil granule proteins in inflammatory bowel disease. Scand J Gastroenterol. 2019;54(10):1237–1244.
   PubMed Web of Science ®Google Scholar
• Abedin N, Seemann T, Kleinfeld S, et al. Fecal eosinophil cationic protein is a diagnostic and predictive biomarker in young adults with inflammatory bowel disease. J Clin Med. 2019;8(12):2025.
   PubMed Web of Science ®Google Scholar
• Trasolini R, Zhu K, Klemm N, et al. Fecal leukocyte esterase, an alternative biomarker to fecal calprotectin in inflammatory bowel disease: a Pilot series. Gastro Hep Adv. 2022;1(1):45–51.
   Google Scholar
• Shinzaki S, Matsuoka K, Iijima H, et al. Leucine-rich alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis. J Crohns Colitis. 2017;11(1):84–91.
   PubMed Web of Science ®Google Scholar
• Nakov R, Velikova T, Nakov V, et al. Trefoil factor 3 is highly predictive of complete mucosal healing independently and in combination with C-Reactive protein in patients with ulcerative colitis. J Gastrointest Liver Dis JGLD. 2019;28:169–174. doi: 10.15403/jgld-177
   PubMed Web of Science ®Google Scholar
• Wakai M, Hayashi R, Tanaka S, et al. Serum amyloid a is a better predictive biomarker of mucosal healing than C-reactive protein in ulcerative colitis in clinical remission. BMC Gastroenterol. 2020;20(1):85.
   PubMed Web of Science ®Google Scholar
• Jaenisch SE, Abbott CA, Gorrell MD, et al. Circulating Dipeptidyl peptidase activity is a potential biomarker for inflammatory bowel disease. Clin Transl Gastroenterol. 2022;13(1):e00452.
   PubMed Web of Science ®Google Scholar
• Pinto-Lopes P, Afonso J, Pinto-Lopes R, et al. Serum Dipeptidyl peptidase 4: a predictor of disease activity and prognosis in inflammatory bowel disease. Inflamm Bowel Dis. 2020;26(11):1707–1719.
   PubMed Web of Science ®Google Scholar
• Maeda K, Nakamura M, Yamamura T, et al. Gelsolin as a potential biomarker for endoscopic activity and mucosal healing in ulcerative colitis. Biomedicines. 2022;10(4):872.
   PubMed Web of Science ®Google Scholar
• Shiraishi K, Furukawa S, Yagi S, et al. Serum globulin is associated with endoscopic findings and mucosal healing in Japanese patients with ulcerative colitis. Dig Dis Sci. 2022;67(1):233–240.
   PubMed Web of Science ®Google Scholar
• Verstockt S, Verstockt B, Machiels K, et al. Oncostatin M is a biomarker of diagnosis, worse disease prognosis, and therapeutic nonresponse in inflammatory bowel disease. Inflamm Bowel Dis. 2021;27(10):1564–1575. doi: 10.1093/ibd/izab032
   PubMed Web of Science ®Google Scholar
• Guo A, Ross C, Chande N, et al. High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists. Sci Rep. 2022;12(1):1185.
   PubMed Web of Science ®Google Scholar
• West NR, Hegazy AN, Owens BMJ, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017;23(5):579–589.
   PubMed Web of Science ®Google Scholar
• Nishida Y, Hosomi S, Watanabe K, et al. Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis. Scand J Gastroenterol. 2018;53(5):579–585.
   PubMed Web of Science ®Google Scholar
• Bertani L, Rossari F, Barberio B, et al. Novel prognostic biomarkers of mucosal healing in ulcerative colitis patients treated with anti-TNF: neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio. Inflamm Bowel Dis. 2020;26(10):1579–1587.
   PubMed Web of Science ®Google Scholar
• Mortensen JH, Godskesen LE, Jensen MD, et al. Fragments of citrullinated and MMP-degraded vimentin and MMP-degraded type III collagen are Novel serological biomarkers to differentiate Crohn’s disease from ulcerative colitis. J Crohns Colitis. 2015;9(10):863–872.
   PubMed Web of Science ®Google Scholar
• Domislovic V, Høg Mortensen J, Lindholm M, et al. Inflammatory biomarkers of extracellular matrix remodeling and disease activity in Crohn’s disease and ulcerative colitis. J Clin Med. 2022;11(19):5907.
   PubMed Web of Science ®Google Scholar
• Kalla R, Adams AT, Bergemalm D, et al. Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease. J Crohns Colitis. 2021;15(5):699–708.
   PubMed Web of Science ®Google Scholar
• Sudhakar P, Salomon B, Verstockt B, et al. DOP79 biomarkers for IBD using OLINK proteomics inflammation panel: preliminary results from the COLLIBRI consortium. J Crohns Colitis. 2022;16(Supplement_1):i123–i124.
   Google Scholar
• Bergemalm D, Andersson E, Hultdin J, et al. Systemic Inflammation in Preclinical Ulcerative Colitis. Gastroenterology. 2021;161(5):1526–1539.e9.
   PubMed Web of Science ®Google Scholar
• Torres J, Petralia F, Sato T, et al. Serum biomarkers identify patients who will develop inflammatory bowel diseases up to 5 years before diagnosis. Gastroenterology. 2020;159(1):96–104.
   PubMed Web of Science ®Google Scholar
• Bourgonje AR, von Martels JZH, Gabriëls RY, et al. A combined set of four serum inflammatory biomarkers reliably predicts endoscopic disease activity in inflammatory bowel disease. Front Med. 2019;6:251. doi: 10.3389/fmed.2019.00251
   PubMed Web of Science ®Google Scholar
• Baldan-Martin M, Azkargorta M, Iloro I, et al. P018 proteomic profile of serum and urine in newly diagnosed patients with inflammatory bowel disease: new approach for biomarker discovery. J Crohns Colitis. 2022;16(Supplement_1):i145.
   Google Scholar
• Andersson E, Bergemalm D, Kruse R, et al. Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles. PLoS One. 2017;12(10):e0186142.
   PubMed Web of Science ®Google Scholar
• Heier CR, Fiorillo AA, Chaisson E, et al. Identification of pathway-specific serum biomarkers of response to glucocorticoid and infliximab treatment in children with inflammatory bowel disease. Clin Transl Gastroenterol. 2016;7(9):e192.
   PubMedGoogle Scholar
• Adams A, Gupta V, Mohsen W, et al. Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response. Gut. 2023;72(3):433–442.
   PubMed Web of Science ®Google Scholar
• Grant RK, Jones G-R, Plevris N, et al. The ACE (albumin, CRP and endoscopy) index in acute colitis: a simple clinical index on admission that predicts outcome in patients with acute ulcerative colitis. Inflamm Bowel Dis. 2021;27(4):451–457.
   PubMed Web of Science ®Google Scholar
• Gibson DJ, Hartery K, Doherty J, et al. Crp/albumin ratio: an early predictor of steroid responsiveness in acute severe ulcerative colitis. J Clin Gastroenterol. 2018;52(6):e48–e52.
   PubMed Web of Science ®Google Scholar
• Header DA, Aboelwafa RA, Elkeleny MR, et al. C-reactive protein/albumin ratio (CAR) as a marker for detecting acute severe ulcerative colitis in Egyptian patients. Rev Gastroenterol Mex Engl. 2022;87(4):447–454.
   Web of Science ®Google Scholar
• Yagi S, Furukawa S, Shiraishi K, et al. The albumin to globulin ratio is associated with clinical outcome in Japanese patients with ulcerative colitis. Ann Coloproctology. 2023;39(2):155–163.
   PubMed Web of Science ®Google Scholar
• Kalla R, Adams AT, Nowak JK, et al. Analysis of systemic epigenetic alterations in inflammatory bowel disease: defining geographical, genetic and immune-inflammatory influences on the circulating methylome. J Crohns Colitis. 2023;17(2):170–184.
   PubMed Web of Science ®Google Scholar
• Gasparetto M, Payne F, Nayak K, et al. Transcription and DNA methylation patterns of blood-derived CD8+ T cells are associated with age and inflammatory bowel disease but do not predict prognosis. Gastroenterology. 2020;160(1):232–244.e7.
   PubMed Web of Science ®Google Scholar
• Adams AT, Kennedy NA, Hansen R, et al. Two-stage genome-wide methylation profiling in childhood-onset Crohnʼs disease implicates epigenetic alterations at the VMP1/MIR21 and HLA loci. Inflamm Bowel Dis. 2014;20(10):1784–1793.
   PubMed Web of Science ®Google Scholar
• Kalla R, Adams AT, Satsangi J. Blood-based DNA methylation in Crohn’s disease and severity of intestinal inflammation. Transl Gastroenterol Hepatol. 2019;4:76. doi: 10.21037/tgh.2019.10.03
   PubMed Web of Science ®Google Scholar
• Ventham NT, Kennedy NA, Adams AT, et al. Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease. Nat Commun. 2016;7(1):13507.
   PubMedGoogle Scholar
• Joustra V, Hageman IL, Satsangi J, et al. Systematic review and meta-analysis of peripheral blood DNA methylation studies in inflammatory bowel disease. J Crohns Colitis. 2023;17(2):185–198.
   PubMed Web of Science ®Google Scholar
• Venkateswaran S, Somineni HK, Matthews JD, et al. Longitudinal DNA methylation profiling of the rectal mucosa identifies cell-specific signatures of disease status, severity and clinical outcomes in ulcerative colitis cell-specific DNA methylation signatures of UC. Clin Epigenetics. 2023;15(1):50.
   PubMed Web of Science ®Google Scholar
• Burakoff R, Chao S, Perencevich M, et al. Blood-based biomarkers can differentiate ulcerative colitis from crohnʼs disease and noninflammatory diarrhea. Inflamm Bowel Dis. 2011;17(8):1719–1725.
   PubMed Web of Science ®Google Scholar
• Biasci D, Lee JC, Noor NM, et al. A blood-based prognostic biomarker in IBD. Gut. 2019;68(8):1386–1395.
   PubMed Web of Science ®Google Scholar
• Nowak JK, Adams AT, Kalla R, et al. Characterization of the circulating transcriptomic landscape in inflammatory bowel disease provides evidence for dysregulation of multiple transcription factors including NFE2, SPI1, CEBPB, and IRF2. J Crohns Colitis. 2022;16(8):1255–1268.
   PubMed Web of Science ®Google Scholar
• Kalla R, Adams AT, Ventham NT, et al. Whole blood profiling of T-cell derived miRNA allows the development of prognostic models in inflammatory bowel disease. J Crohns Colitis. 2020;14(12):1724–1733.
   PubMed Web of Science ®Google Scholar
• Yarani R, Shojaeian A, Palasca O, et al. Differentially expressed miRnas in ulcerative colitis and Crohn’s disease. Front Immunol. 2022;13:865777. doi: 10.3389/fimmu.2022.865777
   PubMed Web of Science ®Google Scholar
• Zhou J, Liu J, Gao Y, et al. miRNA-Based potential biomarkers and new molecular insights in ulcerative colitis. Front Pharmacol. 2021 [cited 2023 Aug 13]; 12. Internet: 10.3389/fphar.2021.707776
   Web of Science ®Google Scholar
• Vatn SS, Lindstrøm JC, Moen AEF, et al. Mucosal gene transcript signatures in treatment naïve inflammatory bowel disease: a comparative analysis of disease to symptomatic and healthy controls in the European IBD-Character cohort. Clin Exp Gastroenterol. 2022;15:5–25. doi: 10.2147/CEG.S343468
   PubMed Web of Science ®Google Scholar
• Ostrowski J, Dabrowska M, Lazowska I, et al. Redefining the practical utility of blood transcriptome biomarkers in inflammatory bowel diseases. J Crohns Colitis. 2019;13(5):626–633.
   PubMed Web of Science ®Google Scholar
• Wu Z, Bi Y. Potential role of MALT1 as a candidate biomarker of disease surveillance and treatment response prediction in inflammatory bowel disease patients. J Clin Lab Anal. 2022;36(2):e24130. doi: 10.1002/jcla.24130
   PubMed Web of Science ®Google Scholar
• Mo A, Nagpal S, Gettler K, et al. Stratification of risk of progression to colectomy in ulcerative colitis via measured and predicted gene expression. Am J Hum Genet. 2021;108(9):1765–1779.
   PubMed Web of Science ®Google Scholar
• Clerc F, Novokmet M, Dotz V, et al. Plasma N-Glycan signatures are associated with features of inflammatory bowel diseases. Gastroenterology. 2018;155(3):829–843.
   PubMed Web of Science ®Google Scholar
• Shubhakar A, Jansen B, Adams A, et al. DOP10 serum N-glycomic biomarkers predict treatment escalation in inflammatory bowel disease. J Crohns Colitis. 2019;13(Supplement_1):S032–S033.
   Google Scholar
• Shubhakar A, Jansen BC, Adams AT, et al. Serum N-Glycomic biomarkers predict treatment escalation in inflammatory bowel disease. J Crohns Colitis. 2023;17(6):919–932.
   PubMed Web of Science ®Google Scholar
• Pereira MS, Maia L, Azevedo LF, et al. A [Glyco]biomarker that predicts failure to Standard therapy in ulcerative colitis patients. J Crohns Colitis. 2019;13(1):39–49.
   PubMed Web of Science ®Google Scholar
• Probert F, Walsh A, Jagielowicz M, et al. Plasma nuclear magnetic resonance Metabolomics discriminates between high and low endoscopic activity and predicts progression in a prospective cohort of patients with ulcerative colitis. J Crohns Colitis. 2018;12(11):1326–1337.
   PubMed Web of Science ®Google Scholar
• Ghimire H, Viennois E, Hu X, et al. Infrared spectrometric biomarkers for ulcerative colitis screening using human serum samples. J Biophoto. 2022;15(6):e202100307.
   PubMed Web of Science ®Google Scholar
• Berry N, Sinha SK, Bhattacharya A, et al. Role of positron emission tomography in assessing disease activity in ulcerative colitis: comparison with biomarkers. Dig Dis Sci. 2018;63(6):1541–1550.
   PubMed Web of Science ®Google Scholar
• Borren NZ, Plichta D, Joshi AD, et al. Multi-“-omics” profiling in patients with quiescent inflammatory bowel disease identifies biomarkers predicting relapse. Inflamm Bowel Dis. 2020;26(10):1524–1532.
   PubMed Web of Science ®Google Scholar
• Integrated bile acid profile analysis for the non-invasive staging diagnosis of ulcerative colitis. medRxiv [Internet]. [cited 2022 Nov 8]. Available from: https://www.medrxiv.org/content/10.1101/2022.03.14.22272391v1
   Google Scholar
• Sun Q, Tang Y, Dai L, et al. Serum bile acid metabolites predict the therapeutic effect of Mesalazine in patients with ulcerative colitis. J Proteome Res. 2023;22(4):1287–1297.
   PubMed Web of Science ®Google Scholar
• Jagt JZ, Struys EA, Ayada I, et al. Fecal amino acid analysis in newly diagnosed pediatric inflammatory bowel disease: a multicenter case-control study. Inflamm Bowel Dis. 2022;28(5):755–763.
   PubMed Web of Science ®Google Scholar
• Zhou G, Liu H, Wei P, et al. Amino acids-targeted metabolomics reveals novel diagnostic biomarkers for ulcerative colitis and Crohn’s disease. Amino Acids. 2023;55(3):349–358.
   PubMed Web of Science ®Google Scholar
• Liu Z, Tang H, Liang H, et al. Dyslipidaemia is associated with severe disease activity and poor prognosis in ulcerative colitis: a retrospective cohort study in China. Nutrients. 2022;14(15):3040.
   PubMed Web of Science ®Google Scholar
• Manfredi M, Conte E, Barberis E, et al. Integrated serum proteins and fatty acids analysis for putative biomarker discovery in inflammatory bowel disease. J Proteomics. 2019;195:138–149. doi: 10.1016/j.jprot.2018.10.017
   PubMed Web of Science ®Google Scholar
• Galipeau HJ, Caminero A, Turpin W, et al. Novel fecal biomarkers that precede clinical diagnosis of ulcerative colitis. Gastroenterology. 2021;160(5):1532–1545.
   PubMed Web of Science ®Google Scholar
• Iwasawa K, Suda W, Tsunoda T, et al. Dysbiosis of the salivary microbiota in pediatric-onset primary sclerosing cholangitis and its potential as a biomarker. Sci Rep. 2018;8(1):5480.
   PubMedGoogle Scholar
• Olbjørn C, Cvancarova Småstuen M, Thiis-Evensen E, et al. Fecal microbiota profiles in treatment-naïve pediatric inflammatory bowel disease – associations with disease phenotype, treatment, and outcome. Clin Exp Gastroenterol. 2019;12:37–49. doi: 10.2147/CEG.S186235
   PubMed Web of Science ®Google Scholar
• Olbjørn C, Småstuen MC, Moen AEF. Targeted analysis of the Gut microbiome for diagnosis, prognosis and treatment individualization in pediatric inflammatory bowel disease. Microorganisms. 2022;10(7):1273. doi: 10.3390/microorganisms10071273
   PubMed Web of Science ®Google Scholar
• Vatn S, Carstens A, Kristoffersen AB, et al. Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European multicentre study (IBD-Character). Scand J Gastroenterol. 2020;55(10):1146–1156.
   PubMed Web of Science ®Google Scholar
• Liu J, Fang H, Hong N, et al. Gut microbiome and metabonomic profile predict early remission to anti-integrin therapy in patients with moderate to severe ulcerative colitis. Microbiol Spectr. 2023;11(3):e0145723.
   PubMed Web of Science ®Google Scholar
• Rees NP, Shaheen W, Quince C, et al. Systematic review of donor and recipient predictive biomarkers of response to faecal microbiota transplantation in patients with ulcerative colitis. EBioMedicine. 2022;81:104088. doi: 10.1016/j.ebiom.2022.104088
   PubMed Web of Science ®Google Scholar
• van Thiel IAM, Rahman S, Hakvoort TBM, et al. Fecal Filobasidium is associated with clinical remission and endoscopic response following fecal microbiota transplantation in mild-to-moderate ulcerative colitis. Microorganisms. 2022;10(4):737.
   PubMed Web of Science ®Google Scholar
• Nishida Y, Hosomi S, Yamagami H, et al. Novel prognostic biomarkers of pouchitis after ileal pouch-anal anastomosis for ulcerative colitis: neutrophil-to-lymphocyte ratio. PLoS One. 2020;15(10):e0241322.
   PubMed Web of Science ®Google Scholar
• Okba AM, Amin MM, Abdelmoaty AS, et al. Neutrophil/Lymphocyte ratio and lymphocyte/monocyte ratio in ulcerative colitis as non-invasive biomarkers of disease activity and severity. Autoimmun Highlights. 2019;10(1):4.
   PubMedGoogle Scholar
• Kurimoto N, Nishida Y, Hosomi S, et al. Neutrophil-to-lymphocyte ratio may predict clinical relapse in ulcerative colitis patients with mucosal healing. PLoS One. 2023;18(1):e0280252.
   PubMed Web of Science ®Google Scholar
• Anderson A, Cherfane C, Click B, et al. Monocytosis is a biomarker of severity in inflammatory bowel disease: analysis of a 6-year prospective natural history registry. Inflamm Bowel Dis. 2022;28(1):70–78.
   PubMed Web of Science ®Google Scholar
• Gettler K, Levantovsky R, Moscati A, et al. Common and rare variant prediction and penetrance of IBD in a large, multi-ethnic Health System-Based Biobank Cohort. Gastroenterol. 2021;160(5):1546–1557.
   PubMed Web of Science ®Google Scholar
• Kikut J, Mokrzycka M, Drozd A, et al. Involvement of proinflammatory arachidonic acid (ARA) derivatives in Crohn’s disease (CD) and ulcerative colitis (UC). J Clin Med. 2022;11(7):1861.
   PubMed Web of Science ®Google Scholar
• Debourdeau E, Chamard C, Carriere I, et al. Retinal microcirculation changes in Crohn’s disease patients under biologics, a potential biomarker of severity: a Pilot study. J Pers Med. 2022;12(2):230.
   PubMed Web of Science ®Google Scholar
• Zittan E, Steinhart AH, Aran H, et al. The Toronto IBD Global endoscopic Reporting [TIGER] score: a single, easy to use endoscopic score for both Crohn’s disease and ulcerative colitis patients. J Crohns Colitis. 2022;16(4):544–553.
   PubMed Web of Science ®Google Scholar
• Rowan CR, Cullen G, Mulcahy HE, et al. DUBLIN [degree of ulcerative colitis burden of Luminal inflammation] score, a simple method to quantify inflammatory burden in ulcerative colitis. J Crohns Colitis. 2019;13(11):1365–1371.
   PubMed Web of Science ®Google Scholar
• Gordon IO, Agrawal N, Willis E, et al. Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation. Aliment Pharmacol Ther. 2018;47(7):922–939.
   PubMed Web of Science ®Google Scholar
• Mortensen JH, Lindholm M, Langholm LL, et al. The intestinal tissue homeostasis – the role of extracellular matrix remodeling in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2019;13(10):977–993.
   PubMed Web of Science ®Google Scholar
• Boyapati RK, Dorward DA, Tamborska A, et al. Mitochondrial DNA is a pro-inflammatory Damage-associated molecular Pattern Released During active IBD. Inflamm Bowel Dis. 2018;24(10):2113–2122.
   PubMed Web of Science ®Google Scholar
• Mitochondrial DAMPs as mechanistic biomarkers of mucosal inflammation in Crohn’s disease: study protocol for prospective longitudinal cohort study in Scotland. medRxiv [Internet]. [cited 2022 Nov 8]. Available from: https://www.medrxiv.org/content/10.1101/2022.03.21.22270313v1
   Google Scholar
• Argmann C, Hou R, Ungaro RC, et al. Biopsy and blood-based molecular biomarker of inflammation in IBD. Gut [Internet]. 2022 [cited 2023 Jan 17]. Available from: https://gut.bmj.com/content/early/2022/09/14/gutjnl-2021-326451
   Google Scholar
• Khanna R, Narula N, Feagan BG. The role of biomarkers in clinical trials of inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(8):1619–1623. doi: 10.1093/ibd/izy195
   PubMed Web of Science ®Google Scholar
• Gabriëls RY, Bourgonje AR, von Martels J, et al. P577 Mucosal eosinophil abundance in non-inflamed colonic tissue predict response to vedolizumab induction therapy in inflammatory bowel disease. J Crohns Colitis. 2022;16(Supplement_1):i517–i518.
   PubMedGoogle Scholar
• Roosenboom B, Wahab PJ, Smids C, et al. Mucosal α4β7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis. Inflamm Bowel Dis. 2023;zad123. doi: 10.1093/ibd/izad123
   Web of Science ®Google Scholar
• Telesco SE, Brodmerkel C, Zhang H, et al. Gene expression signature for prediction of Golimumab response in a phase 2a open-label trial of patients with ulcerative colitis. Gastroenterology. 2018;155(4):1008–1011.e8.
   PubMed Web of Science ®Google Scholar
• Scheer J. Gould and Goldman: deadly deceit--a defense. Health Phys. 1991;61(2):279–280.
   PubMed Web of Science ®Google Scholar